{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:17:05Z","timestamp":1793247425849,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["222489\/Z\/21\/Z"],"award-info":[{"award-number":["222489\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AI163395"],"award-info":[{"award-number":["R01AI163395"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["RCHS0235 950-232424"],"award-info":[{"award-number":["RCHS0235 950-232424"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["1U19AI171443"],"award-info":[{"award-number":["1U19AI171443"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014054","name":"Drugs for Neglected Diseases initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["177958"],"award-info":[{"award-number":["177958"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["487578"],"award-info":[{"award-number":["487578"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["R24OD026440-03S1"],"award-info":[{"award-number":["R24OD026440-03S1"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["RCHS0235 950-232424"],"award-info":[{"award-number":["RCHS0235 950-232424"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.isci.2024.109049","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T12:59:50Z","timestamp":1706619590000},"page":"109049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens"],"prefix":"10.1016","volume":"27","author":[{"given":"Irfan","family":"Ullah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Escudie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Scandale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoela","family":"Gilani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Gendron-Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"Gaudette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Mowbray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Fraisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e","family":"Bazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Finzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walther","family":"Mothes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chatelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep D.","family":"Uchil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2024.109049_bib1","first-page":"1438","article-title":"Global COVID-19 Death Toll May Be Triple the Reported Deaths","volume":"327","author":"Larkin","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.isci.2024.109049_bib2","doi-asserted-by":"crossref","first-page":"ofac124","DOI":"10.1093\/ofid\/ofac124","article-title":"COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective","volume":"9","author":"Marcelin","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.isci.2024.109049_bib3","article-title":"Public health impact of covid-19 vaccines in the US: observational study","volume":"377","author":"Suthar","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.isci.2024.109049_bib4","doi-asserted-by":"crossref","first-page":"o867","DOI":"10.1136\/bmj.o867","article-title":"The benefits of large scale covid-19 vaccination","volume":"377","author":"Dye","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.isci.2024.109049_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-021-03681-2","article-title":"Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans","volume":"596","author":"Alter","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.isci.2024.109049_bib6","unstructured":"Agency, U.H.S. COVID-19 Vaccine Surveillance Report Week 19."},{"key":"10.1016\/j.isci.2024.109049_bib7","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-2600(22)00101-1","article-title":"Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study","volume":"10","author":"Tartof","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.isci.2024.109049_bib8","article-title":"WHO declares end to COVID-19's emergency phase","author":"Lenharo","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.isci.2024.109049_bib9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41467-022-29104-y","article-title":"De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report","volume":"13","author":"Gandhi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2024.109049_bib10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/ajcp\/aqaa064","article-title":"Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources","volume":"153","author":"Abdalhamid","year":"2020","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.isci.2024.109049_bib11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40265-022-01684-5","article-title":"Molnupiravir: First Approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.isci.2024.109049_bib12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.isci.2024.109049_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009553","article-title":"Favipiravir treatment prolongs the survival in a lethal mouse model intracerebrally inoculated with Jamestown Canyon virus","volume":"15","author":"Kato","year":"2021","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.isci.2024.109049_bib14","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1007\/s43440-020-00175-2","article-title":"Favipiravir use for SARS CoV-2 infection","volume":"72","author":"Boretti","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.isci.2024.109049_bib15","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.isci.2024.109049_bib16","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00044-022-02951-6","article-title":"The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations","volume":"31","author":"Joyce","year":"2022","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.isci.2024.109049_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105430","article-title":"Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice","volume":"208","author":"Jeong","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.isci.2024.109049_bib18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41467-022-28354-0","article-title":"The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern","volume":"13","author":"Abdelnabi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2024.109049_bib19","article-title":"Combined molnupiravir and nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in Rhesus Macaques","author":"Rosenke","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.isci.2024.109049_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160108","article-title":"Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model","volume":"7","author":"Rosenke","year":"2022","journal-title":"JCI insight"},{"key":"10.1016\/j.isci.2024.109049_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.isci.2024.109049_bib22","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-023-06649-6","article-title":"A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes","volume":"623","author":"Sanderson","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.isci.2024.109049_bib23","doi-asserted-by":"crossref","first-page":"e2473","DOI":"10.1002\/rmv.2473","article-title":"Efficacy and safety of paxlovid (nirmatrelvir\/ritonavir) in the treatment of COVID-19: An updated meta-analysis and trial sequential analysis","volume":"33","author":"Tian","year":"2023","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.isci.2024.109049_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106708","article-title":"Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics","volume":"61","author":"Focosi","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.isci.2024.109049_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03331-22","article-title":"Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2","volume":"10","author":"Wagoner","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.isci.2024.109049_bib26","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.immuni.2021.08.015","article-title":"Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy","volume":"54","author":"Ullah","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2024.109049_bib27","article-title":"The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice","volume":"4","author":"Ullah","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2024.109049_bib28","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3389\/fmicb.2022.840757","article-title":"Heterogeneous infectivity and pathogenesis of SARS-CoV-2 variants beta, delta and omicron in transgenic K18-hACE2 and wildtype mice","volume":"13","author":"Tarr\u00e9s-Freixas","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.isci.2024.109049_bib29","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201707","article-title":"Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients","volume":"218","author":"Rodrigues","year":"2021","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.isci.2024.109049_bib30","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.3389\/fimmu.2020.583373","article-title":"The inflammasome in times of COVID-19","volume":"11","author":"de Rivero Vaccari","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2024.109049_bib31","doi-asserted-by":"crossref","DOI":"10.4081\/monaldi.2020.1289","article-title":"Emerging prophylaxis strategies against COVID-19","volume":"90","author":"Agrawal","year":"2020","journal-title":"Monaldi Arch. Chest Dis."},{"key":"10.1016\/j.isci.2024.109049_bib32","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3390\/v15040999","article-title":"Virulence Profiles of Wild-Type, P. 1 and Delta SARS-CoV-2 Variants in K18-hACE2 Transgenic Mice","volume":"15","author":"da Silva Santos","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.isci.2024.109049_bib33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J.\u00a0Basic Clin. Pharm."},{"key":"10.1016\/j.isci.2024.109049_bib36","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41385-021-00437-z","article-title":"Human small intestinal infection by SARS-CoV-2 is characterized by a mucosal infiltration with activated CD8+ T\u00a0cells","volume":"14","author":"Lehmann","year":"2021","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.isci.2024.109049_bib37","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1097\/PG9.0000000000000152","article-title":"Persistent SARS-CoV-2 nucleocapsid protein presence in the intestinal epithelium of a pediatric patient 3\u00a0months after acute infection","volume":"3","author":"Arostegui","year":"2022","journal-title":"JPGN Rep."},{"key":"10.1016\/j.isci.2024.109049_bib38","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.stem.2020.06.020","article-title":"Inflammatory Signals Induce AT2 Cell-Derived Damage-Associated Transient Progenitors that Mediate Alveolar Regeneration","volume":"27","author":"Choi","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.isci.2024.109049_bib39","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1038\/s41467-020-17358-3","article-title":"Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis","volume":"11","author":"Strunz","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2024.109049_bib40","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-04441-6","article-title":"SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters","volume":"603","author":"Halfmann","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.isci.2024.109049_bib41","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41577-021-00588-x","article-title":"Inflammasome activation at the crux of severe COVID-19","volume":"21","author":"Vora","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2024.109049_bib42","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2202012119","article-title":"Caspase-4\/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and immunothrombosis","volume":"119","author":"Eltobgy","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2024.109049_bib43","article-title":"Inflammasome activation in infected macrophages drives COVID-19 pathology","author":"Sefik","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.isci.2024.109049_bib44","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-022-04702-4","article-title":"Fc\u03b3R-mediated SARS-CoV-2 infection of monocytes activates inflammation","volume":"606","author":"Junqueira","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.isci.2024.109049_bib45","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nature12940","article-title":"Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection","volume":"505","author":"Doitsh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.isci.2024.109049_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.671","article-title":"Comparative evaluation of authorized drugs for treating Covid-19 patients","volume":"5","author":"Islam","year":"2022","journal-title":"Health Sci. Rep."},{"key":"10.1016\/j.isci.2024.109049_bib47","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S2666-5247(21)00278-0","article-title":"The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era","volume":"3","author":"Fan","year":"2022","journal-title":"Lancet. Microbe"},{"key":"10.1016\/j.isci.2024.109049_bib48","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2024.109049_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114367","article-title":"Paxlovid (Nirmatrelvir\/Ritonavir): A new approach to Covid-19 therapy?","volume":"162","author":"Hashemian","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.isci.2024.109049_bib50","article-title":"Impact of extended-course oral nirmatrelvir\/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations","author":"Cohen","year":"2023","journal-title":"Res. Sq."},{"key":"10.1016\/j.isci.2024.109049_bib51","article-title":"Genetic consequences of effective and suboptimal dosing with mutagenic drugs in a hamster model of SARS-CoV-2 infection","author":"Illingworth","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.isci.2024.109049_bib52","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/d41586-023-00347-z","article-title":"COVID drug drives viral mutations - and now some want to halt its use","volume":"614","author":"Callaway","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.isci.2024.109049_bib53","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ymthe.2020.12.016","article-title":"Synergistic and Antagonistic Drug Combinations against SARS-CoV-2","volume":"29","author":"Bobrowski","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2024.109049_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.05.005","article-title":"An overview of in\u00a0vitro, ex\u00a0vivo and in\u00a0vivo models for studying the transport of drugs across intestinal barriers","volume":"175","author":"Xu","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.isci.2024.109049_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103595","article-title":"The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model","volume":"72","author":"Abdelnabi","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2024.109049_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105430","article-title":"Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice","volume":"208","author":"Jeong","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.isci.2024.109049_bib57","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.166485","article-title":"Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques","volume":"8","author":"Rosenke","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.isci.2024.109049_bib58","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","year":"2021","journal-title":"N.\u00a0Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.isci.2024.109049_bib59","article-title":"SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity","volume":"3","author":"Richardson","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2024.109049_bib60","article-title":"Fc effector cross-reactivity: A hidden arsenal against SARS-CoV-2's evasive maneuvering","volume":"3","author":"Grunst","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2024.109049_bib61","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-021-04017-w","article-title":"Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy","volume":"599","author":"Yamin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.isci.2024.109049_bib62","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s41586-022-05542-y","article-title":"SARS-CoV-2 infection and persistence in the human body and brain at autopsy","volume":"612","author":"Stein","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.isci.2024.109049_bib63","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1038\/s41467-022-34068-0","article-title":"Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study","volume":"13","author":"Etter","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2024.109049_bib64","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200960119","article-title":"Morphological, cellular, and molecular basis of brain infection in COVID-19 patients","volume":"119","author":"Crunfli","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2024.109049_bib65","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41586-022-04569-5","article-title":"SARS-CoV-2 is associated with changes in brain structure in UK Biobank","volume":"604","author":"Douaud","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.isci.2024.109049_bib66","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.isci.2024.109049_bib72","article-title":"Rapid Quantification and Neutralization Assays for Novel Coronavirus SARS-CoV-2\u00a0Using Avicel RC-591 Semi-Solid Overlay","author":"Honko","year":"2020","journal-title":"Preprints.org"},{"key":"10.1016\/j.isci.2024.109049_bib67","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1038\/s41467-021-23779-5","article-title":"A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses","volume":"12","author":"Amarilla","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2024.109049_bib68","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood.2020008367","article-title":"Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4\u00a0months after symptom onset","volume":"136","author":"Perreault","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.isci.2024.109049_bib69","article-title":"Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD","volume":"26","author":"Chen","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.isci.2024.109049_bib70","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/cid\/ciaa460","article-title":"Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients","volume":"71","author":"Xiao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.isci.2024.109049_bib71","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004224002700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004224002700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:20:14Z","timestamp":1753867214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004224002700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2589004224002700"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2024.109049","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2024.109049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"109049"}}